Combination therapy for the treatment of autoimmune diseases

Abstract

The present invention pertains to compounds and their combination for use in the prevention or therapy of a subject suffering from an autoimmune disease such as diabetes type 1. Provided are antagonists of T-cells that are used in combination with antagonists of the cytokine CXCL10, sequentially or concomitantly, in a subject suffering from an autoimmune disease, in particular diabetes type 1.

1 . A composition comprising (i) a T-cell-antagonist and (ii) a C-X-C motif chemokine 10 (CXCL10)-antagonist formulated for concomitant or sequential use in the prevention or treatment of an autoimmune disease. 
     
     
         2 . A method for the prevention or treatment of an autoimmune disease in a subject, the method comprising administering to said subject a therapeutically effective amount of a T-cell-antagonist and a C-X-C motif chemokine 10 (CXCL10)-antagonist. 
     
     
         3 . The method according to  claim 2 , wherein said T-cell-antagonist and said CXCL10-antagonist are administered to said subject sequentially, or concomitantly. 
     
     
         4 . The method according to  claim 2 , wherein said autoimmune disease is diabetes type 1. 
     
     
         5 . The method according to  claim 2 , wherein said antagonist is selected from the group consisting of inhibitory RNA, inhibitory antibodies, and small molecules. 
     
     
         6 . The method according to  claim 2 , wherein said T-cell-antagonist is selected from the group of CD3-antagonists, CD4-antagonists, CD8-antagonists, and combinations of at least one CD4-antagonist and at least one CD8-antagonist. 
     
     
         7 . The method according to  claim 2 , wherein said CXCL10-antagonist is selected from the group consisting of anti-CXCL10 antibodies, soluble CXCR3, and CXCR3 fusion proteins. 
     
     
         8 . The method according to  claim 2 , wherein at least one additional therapeutically effective agent against said autoimmune disease is administered to the patient. 
     
     
         9 . The method according to  claim 8 , wherein said at least one additional therapeutic agent is selected from the group of islet-cell-antigen, rapamycin and probiotics. 
     
     
         10 . The method according to  claim 2 , wherein the subject is a mammal. 
     
     
         11 . The method according to  claim 2 , wherein said subject is suffering from type 1 diabetes and wherein said subject received a pancreas and/or islet transplantation. 
     
     
         12 . The method according to  claim 2 , wherein the subject is suffering from an autoimmune disease. 
     
     
         13 . The method according to  claim 2 , wherein said T-cell antagonist is an antibody against CD3. 
     
     
         14 . The method according to  claim 9 , wherein said probiotic is  Lactococcus lactis.    
     
     
         15 . The method according to  claim 10 , wherein said mammal is a human.